Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Guillermo Lendínez‐Cano
Observed names:
G. Lendinez-Cano,
G. Lendínez-Cano,
Guillermo Lendinez-Cano,
Guillermo Lendínez-Cano
Institutions:
Instituto de Biomedicina de Sevilla,
Hospital Universitario Virgen del Rocío
Observed institutions:
Instituto de Biomedicina de Sevilla,
Hospital Universitario de Valme,
Hospital Universitario Virgen del Rocío,
Hospital San Juan de Dios del Aljarafe,
Universidad de Sevilla
ORCID:
0000-0001-9521-7680
Observed ORCID:
0000-0001-9521-7680
OpenAlex ID:
A5082633663
Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.
2021
·
Xavier Garcia del Muro
, Begoña P. Valderrama
, et al.
·
Journal of Clinical Oncology
·
37
Prospective study of diagnostic accuracy in the detection of high‐grade prostate cancer in biopsy‐naïve patients with clinical suspicion of prostate cancer who underwent the Select MDx test
2021
·
Guillermo Lendínez‐Cano
, Ana Victoria Ojeda‐Claro
, et al.
·
The Prostate
·
31
Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries
2023
·
Steven MacLennan
, Nuno Azevedo
, et al.
·
European Urology
·
25
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
·
Clinical Cancer Research
·
23
Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review
2020
·
Ignacio Osmán-García
, C. Belen Congregado-Ruiz
, et al.
·
Urologia Internationalis
·
16
Comparison of pathological data between prostate biopsy and radical prostatectomy specimen in patients with low to very low risk prostate cancer
2015
·
G. Lendínez-Cano
, J. Alonso-Flores
, et al.
·
Actas Urológicas Españolas (English Edition)
·
13
Comparación de datos anatomopatológicos entre biopsia de próstata y pieza de prostatectomía radical en pacientes con cáncer de bajo y muy bajo riesgo
2015
·
G. Lendínez-Cano
, J. Alonso-Flores
, et al.
·
Actas Urológicas Españolas
·
9
Recent trends in prostate cancer in Spain
2020
·
L. Cayuela
, G. Lendínez-Cano
, et al.
·
Actas Urológicas Españolas (English Edition)
·
7
Tendencias recientes en cáncer de próstata en España
2020
·
L. Cayuela
, G. Lendínez-Cano
, et al.
·
Actas Urológicas Españolas
·
7
Low-dose-rate brachytherapy for prostate cancer in renal transplant recipients
2018
·
I. Rivero-Belenchón
, I. Osmán-García
, et al.
·
Brachytherapy
·
7
Patient's self-reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal
2024
·
Guillermo Lendínez-Cano
, Ángel Vilches-Arenas
, et al.
·
World Journal of Urology
·
6
¿Ha dejado de disminuir la mortalidad por cáncer de próstata en España?
2015
·
A. Cayuela
, L. Cayuela
, et al.
·
Actas Urológicas Españolas
·
6
Has prostate cancer mortality stopped its decline in Spain?
2015
·
A. Cayuela
, L. Cayuela
, et al.
·
Actas Urológicas Españolas (English Edition)
·
4
Differences at diagnosis between long-term survivors and not long-term survivors in metastatic renal cell carcinoma initially treated with TKI
2025
·
Miguel Ángel Gómez-Luque
, Guillermo Lendínez-Cano
, et al.
·
Canadian Journal of Urology
·
2
The influence of age, period, and cohort factors on the incidence of kidney cancer in Spain 1990-2019: Evidence from the global burden of disease study
2024
·
L. Cayuela
, R. Font González
, et al.
·
Actas Urológicas Españolas (English Edition)
·
2
Elective bladder-sparing treatment for muscle invasive bladder cancer
2013
·
G. Lendínez-Cano
, J. Rico-López
, et al.
·
Actas Urológicas Españolas (English Edition)
·
2
Preservación vesical electiva en tumor vesical músculo invasivo
2013
·
G. Lendínez-Cano
, J. Rico-López
, et al.
·
Actas Urológicas Españolas
·
2
[Recurrence and progression after BCG.]
2020
·
Guillermo Lendínez-Cano
, Inés Rivero-Belenchón
, et al.
·
PubMed
·
1
BH3 mimetics sensitize bladder cancer cells to cisplatin treatment
2026
·
Mónica González-Moreno
, Rocío Jiménez-Guerrero
, et al.
·
Cancer Cell International
Integrating patient-reported outcomes into explainable machine learning models for long-term survival prediction in TKI-treated metastatic renal cell carcinoma
2026
·
Miguel Ángel Gómez-Luque
, Guillermo Lendínez-Cano
, et al.
·
Seminars in Oncology
Supplementary Table S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S2 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S4 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Table S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Supplementary Figure S1 from Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
2025
·
Xavier Garcia-del-Muro
, Begoña P. Valderrama
, et al.
Show more works
View as search
Works count:
49
Citation count:
200
H-index:
7
I10-index:
6
Year
Topic
Type